In the IRONMAN trial of 1,137 patients with heart failure and iron deficiency, intravenous ferric derisomaltose lowered recurrent heart failure admissions and cardiovascular death against usual care (rate ratio 0.82), short of statistical significance except in a pre-specified COVID-19 sensitivity analysis.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
In the IRONMAN trial of 1,137 patients with heart failure and iron deficiency, intravenous ferric derisomaltose lowered recurrent heart failure admissions and cardiovascular death against usual care (rate ratio 0.82), short of statistical significance except in a pre-specified COVID-19 sensitivity analysis. · pmid:36347265
In two randomized trials in iron-deficiency anemia, hypophosphatemia followed iron isomaltoside (now called ferric derisomaltose) in about 8% of patients against about 74-75% after ferric carboxymaltose. · pmid:32016310
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Established100%
Proportion of the 2 claims about Ferric derisomaltose (iron isomaltoside 1000) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Ferric derisomaltose (iron isomaltoside 1000) yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. · pmid 32016310 · 2020
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. · pmid 36347265 · 2022
Observational evidence· resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.